Endo Reports Fourth-Quarter and Full-Year 2024 Financial Results
Portfolio Pulse from
Endo, Inc. reported its financial results for 2024, achieving revenue and adjusted EBITDA expectations. XIAFLEX® reached record revenues of $516 million, a 9% increase from 2023. The company provided 2025 revenue guidance of $1,775 to $1,860 million and adjusted EBITDA guidance of $620 to $650 million.
March 13, 2025 | 10:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Endo, Inc. met its 2024 financial expectations with strong performance from XIAFLEX®, which saw a 9% revenue increase. The company provided optimistic 2025 guidance, suggesting potential growth.
Endo's achievement of its 2024 financial targets and the record performance of XIAFLEX® are positive indicators. The optimistic 2025 guidance suggests potential growth, likely boosting investor confidence and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100